Published in final edited form as:

J Labelled Comp Radiopharm. 2008 November ; 51(14): 430–434. doi:10.1002/jlcr.1558.

Synthesis of 19-Trideuterated *ent*-Testosterone and the GABA_A Receptor Potentiators *ent*-Androsterone and *ent*-Etiocholanolone

Shirisha Komarapuri,

Washington Univ. school of Medicine, Developmental Biology

Kathiresan Krishnan, and

Washington Univ. school of Medicine, Developmental Biology

Douglas F. Covey*

Washington Univ. St. Louis, Developmental Biology

Summary

19-Trideuteromethyl enantiomers of androgens namely *ent*-testosterone, *ent*-androsterone and *ent*-etiocholanolone were prepared by total synthesis. The isotope labeling at the carbon-19 angular methyl group was achieved by using deuterated methyl iodide (99.5% *d*₃) for introduction of C-19 before closure of the steroid A-ring. This method yields 19,19,19-trideuterated steroids without increasing the number of steps involved in the total synthesis of *ent*-androgens. Analysis by mass spectrometry showed no loss of deuterium during incorporation of C-19 into *ent*-testosterone. The availability of the compounds will enable these *ent*-androgens to be distinguished by mass spectrometry from their natural enantiomers in future pharmacokinetic and metabolic studies.

Keywords

ent-testosterone-19,19,19-*d*₃; trideuterium label; *ent*-androsterone-19,19,19-*d*₃; *ent*-etiocholanolone-19,19,19-*d*₃; GABA_A receptor modulators

Introduction

Anxiolytic, anticonvulsant, sedative and anesthetic effects of neuroactive steroids are known to occur due to binding of neuroactive steroids to GABA_A receptors.¹ As part of our structure–activity studies of neuroactive steroid modulation of GABA_A receptors, we have investigated the enantioselectivity of neuroactive steroid action at these receptors.² Although we initially found that the naturally occurring enantiomers of several potent neuroactive steroids were more effective modulators of GABA_A receptors than their synthetic non-naturally occurring enantiomers (*ent*-steroids), we recently found that *ent*-androsterone and *ent*-etiocholanolone enhanced GABA-mediated chloride currents at these receptors more effectively than their natural counterparts.³ These previous results suggest that *ent*-androsterone and *ent*-etiocholanolone may have useful *in vivo* activity as GABAergic drugs of the future. In preparation for future pharmacokinetic and metabolic studies we modified the total synthesis of *ent*-testosterone to obtain *ent*-testosterone-19,19,19-*d*₃ (Scheme 1). Modification was easily achieved by using trideuterated methyl iodide in place of methyl iodide during introduction of the C-19 angular methyl group and subsequent closure of the *ent*-steroid A-ring. This

* Corresponding author: Dr. Douglas F. Covey, Department of Developmental Biology, Campus Box 8103, Washington University in St. Louis, School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA, Tel: +1 314 362 1726; Fax: +1 314 362 7058, Email: dcovey@wustl.edu.

trideuterated *ent*-testosterone was then converted into *ent*-androsterone-19,19,19- d_3 and *ent*-etiocholanolone-19,19,19- d_3 by established literature procedures (Figure 1).^{3,4}

Results and discussion

Although deuterium labeling of the C-19 position of natural testosterone has been achieved previously by several different methods,^{5,6} we wanted to incorporate the trideuterated C-19 methyl group into *ent*-testosterone without increasing the number of synthetic steps required to prepare this *ent*-steroid. Accordingly, tricyclic intermediate **1** was first prepared according to the literature.^{7,8}

Compound **1** was then subjected to Li/ liquid NH_3 reduction and the radical anion intermediate produced in the reaction was reacted with methyl iodide- d_3 (99.5% d_3) to obtain the desired C-19 position deuterium labeling in 35% yield. Compound **2** thus obtained was then treated with MeOH under acidic conditions to obtain *ent*-testosterone-19,19,19- d_3 (**3**) in 67% yield. The ^1H -NMR of product **3** lacked the resonance at δ 1.27 ppm for the C-19 methyl group in the natural abundance ^1H -NMR of this compound. Mass spectroscopic analysis of compound **3** showed complete retention (99.5% d_3) of the three deuterium atoms derived from the methyl iodide- d_3 in the product.

The desired *ent*-androsterone-19,19,19- d_3 (**6**) was obtained from *ent*-steroid **3** using procedures reported previously for this transformation on natural abundance *ent*-testosterone (Scheme 2).⁴ Reduction of compound **3** using Li/liquid NH_3 gave *ent*-steroid **4** in 65% yield. Jones oxidation converted ketoalcohol **4** into dione **5** (82% yield) and regio- and stereoselective reduction of dione **5** with K-Selectride[®] gave *ent*-androsterone-19,19,19- d_3 (**6**) in 47 % yield. Because the molecular ion from product **6** is weak, interference from background noise in the mass spectra of this product only permitted the d_3 content of the products to be accurately measured as >95%.

The desired *ent*-etiocholanolone-19,19,19- d_3 (**12**) was also obtained from *ent*-steroid **3** using previously reported procedures described for this transformation on natural abundance *ent*-testosterone (Scheme 3).³ Catalytic hydrogenation of *ent*-steroid **3** using Pd/C gave three isolated products (**4**, **7** and **8**). Compound **4** was easily separated from unseparated products **7** and **8** by column chromatography. Separation of products **7** and **8** required acetylation of the inseparable mixture and column chromatography to separate products **9** and **10**. Saponification of the ketoacetate **9** gave ketoalcohol **7** (37% overall yield). Jones oxidation converted ketoalcohol **7** into dione **11** (77% yield) and regio- and stereoselective reduction of dione **11** with $\text{LiAl}[\text{OC}(\text{CH}_3)_3]_3\text{H}$ gave *ent*-etiocholanolone-19,19,19- d_3 (**12**) in 80% yield. As was the case for product **6**, mass spectrometry could only accurately determine the d_3 content of product **12** to be >95%.

Experimental

Materials and instruments

All solvents were purchased or dried and purified by standard methods. All air and/or moisture sensitive reactions were carried out under N_2 using oven-dried glassware and cooled under vacuum or N_2 . All extraction solvents were dried with anhydrous Na_2SO_4 and the drying agent was removed by filtration before solvent removal. Extraction solvents were removed on a rotary evaporator. Flash chromatography was performed using silica gel (32–63 μm) purchased from Scientific Adsorbents (Atlanta, GA). Optical rotations were determined on a Perkin-Elmer Model 341 polarimeter. Melting points were determined on a Kofler micro hot stage and are uncorrected. IR spectra were recorded as films on a NaCl plate with a Perkin-Elmer Spectrum One FTIR spectrophotometer. NMR spectra were recorded at ambient temperature in CDCl_3

with a 5 mm probe on a Varian Gemini 2000 operating at 300 MHz (^1H) or 75 MHz (^{13}C). ^1H and ^{13}C NMR spectra were referenced to CDCl_3 (δ 7.27) and (δ 77.0), respectively. Mass spectroscopic analyses were performed by the UCR Mass Spectrometry Facility (Riverside, CA). Deuterated methyl iodide (99.5% d_3) was purchased from Cambridge Isotope Laboratories (Andover, MA).

[3R-(3 α ,3 α ,5 α ,6 β ,9 α ,6 β ,9 α ,9 β)]-3-(1,1-Dimethylethoxy)dodecahydro-3 α ,6-dimethyl-6-[2-(2-methyl-1,3-dioxolan-2-yl)ethyl]-7H-benz[e]inden-7-one-3 α ,3 α ,3 α - d_3 (2)—A dry flask was equipped with a mechanical stirrer, addition funnel and a gas bubbler. After cooling the flask to -78°C in a dry ice-acetone bath, NH_3 (~ 1 L) was condensed in the flask. Small pieces of lithium (1.56 g, 0.225 mol) were added, and the blue solution was stirred for 20 min. Enone **1**^{7,8} ($[\alpha]_D = -356.7$ ($c=0.1$, toluene), 22 g, 0.056 mol) was dissolved in THF (100 mL) and added dropwise to the reaction mixture over 30 min. The reaction mixture was maintained at -78°C for 1 h with persistence of blue color. Then, deuterated methyl iodide (14.6 mL, 0.22 mmol) in THF (20 mL) was added dropwise to the solution. This led to a rapid change from blue to yellow color. The reaction was allowed to stir overnight to evaporate the ammonia. After addition of water (1 L) and NH_4Cl (40 g), the product was extracted with EtOAc (3×150 mL) and the combined EtOAc extractions were washed with brine and dried. After solvent evaporation, an orange-brown oil was obtained. Chromatography (silica gel, 15% EtOAc in hexanes) gave product **2** (8.41 g, 35 %) as a white solid: mp $105\text{--}106^\circ\text{C}$; $[\alpha]_D = -34.2$ (CHCl_3 , $c = 1.03$); IR 2966, 1696, 1358, 1201, 1078, 947 cm^{-1} ; ^{13}C -NMR δ 214.83, 110.24, 80.50, 72.20, 64.47, 64.40, 50.39, 50.31, 47.53, 42.42, 38.09, 36.68, 34.71, 32.98, 30.97, 30.72, 28.88, 28.68, 23.73, 23.35, 20.85, 11.54; ^1H -NMR δ 3.93 (4H, m); 3.38 (1H, t, $J = 8.1$ Hz), 2.51 (1H, m), 2.22–2.39 (1H, m), 1.35 (3H, s), 1.13 (9H, s), 0.78 (3H, s); HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{39}\text{D}_3\text{O}_4$, $(\text{M}+\text{Na})^+$ 432.3169; found 432.3178.

ent-Testosterone-19,19,19- d_3 (3)—Benz[e]indene **2** (6.12 g, 0.014 mol) in MeOH (160 mL) and 3 N HCl (40 mL) were heated to reflux for ~ 24 h. After the reaction mixture cooled to room temperature, the MeOH was removed on a rotary evaporator and water (135 mL) was added. The water was extracted with CH_2Cl_2 (3×150 mL) and the combined extracts were washed with NaHCO_3 (50 mL), brine (50 mL) and dried. Solvent evaporation gave a yellow oil. Column chromatography (silica gel, 20% EtOAc in hexanes) yielded product **3** (2.91 g, 67%) as a white solid: mp $151\text{--}153^\circ\text{C}$; $[\alpha]_D = -113$ (CHCl_3 , $c = 1.1$); IR 2942, 1671, 1349, 1179, 940 cm^{-1} ; ^{13}C -NMR δ 199.70, 171.50, 123.72, 81.43, 53.76, 50.36, 42.71, 38.37, 36.32, 35.54, 35.50, 33.83, 32.72, 31.43, 30.24, 23.33, 20.55, 10.97; ^1H -NMR δ 5.73 (1H, s), 3.64 (1H, m), 0.79 (3H, s); HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{25}\text{D}_3\text{O}_2$, MH^+ 292.2356; found 292.2358. No natural abundance MH^+ peak for $\text{C}_{19}\text{H}_{28}\text{O}_2$ was detectable by MS analysis indicating that no deuterium loss accompanied incorporation of the deuterated methyl group derived from deuterated methyl iodide (99.5% d_3) into product **3**.

(5 β ,8 α ,9 β ,10 α ,13 α ,14 β ,17 α)-17-Hydroxyandrostane-3-one-19,19,19- d_3 (4)—A solution of compound **3** (2.1 g, 7.2 mmol) in THF (20 mL) was added to a blue solution of liquid ammonia (500 mL) and dissolved lithium metal (0.16 g, 2.4 mol) in THF (6 mL) and toluene (60 mL) at -78°C . After 30 min, NH_4Cl (3 g) was added portionwise to discharge the blue color and the ammonia was allowed to evaporate. The reaction mixture was diluted with 10% aqueous HCl (50 mL) and extracted with EtOAc (3×25 mL). The combined organic extracts were washed with water (50 mL) and brine (50 mL) and dried. The solvent was removed to give a yellow oil which was purified by column chromatography (silica gel, 20% EtOAc in hexanes to 35% EtOAc in hexanes) to give compound **4** (1.35 g, 65 % yield): mp = $174\text{--}176^\circ\text{C}$; $[\alpha]_D = -32.6$ (CHCl_3 , $c = 0.8$); IR 2925, 1713, 1358, 1201, 1076, 945 cm^{-1} ; ^{13}C -NMR (δ 212, 81.72, 53.82, 50.77, 46.65, 44.62, 42.93, 38.44, 38.08, 36.59, 35.44, 35.39, 31.19,

30.41, 28.74, 23.32, 20.97, 11.09; $^1\text{H-NMR}$ δ 3.63 (1H, t, $J = 8.3$ Hz); 0.75 (3H, s); HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{27}\text{D}_3\text{O}_2$, MH^+ 294.2507; found 294.2512.

(5 β , 8 α , 9 β , 10 α , 13 α , 14 β)-Androstane-3,17-dione (5)—Jones reagent (8 M) was titrated dropwise to a stirred solution of compound **4** (1.38 g, 4.6 mmol) in acetone (100 mL) at 0 °C until an orange color persisted. After an additional 5 min, $i\text{PrOH}$ was also titrated until the excess reagent was destroyed, and water (100 mL) was added. The mixture was extracted with EtOAc (3 $\times$ 50 mL). The combined organic layers were washed with brine (70 mL) and dried. The solvent was removed to give a solid which was recrystallized from hexanes to give the product **5** (1.10 g, 82%) as a white solid: mp 124–125 °C [α]_D = –113 (CHCl_3 , $c = 1$); IR 2971, 1732, 1596, 1200, 1098, 940 cm^{-1} ; $^{13}\text{C-NMR}$ δ 220.78, 211.46, 53.74, 51.13, 47.62, 46.49, 44.50, 38.27, 37.99, 35.72, 35.50, 34.87, 31.40, 30.43, 28.53, 21.68, 20.62, 13.72; $^1\text{H-NMR}$ δ 0.89 (3H, s). HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{25}\text{D}_3\text{O}_2$, MH^+ 292.2350; found 292.2352.

ent-Androsterone-19,19,19- d_3 (6)—K-selectride® (1.0 M solution in THF, 5.2 mL, 5.2 mmol) was added to a stirred solution of compound **5** (1.10 g, 3.7 mmol) in dry THF (5.6 mL) at –78 °C. After 1.5 h, 10% aqueous NaOH (20 mL) and then 30 % aqueous H_2O_2 (7.6 mL) were added. The mixture was allowed to warm to room temperature, stirred for another 30 min, and extracted with CH_2Cl_2 . The combined organic layers were washed with brine and dried. Solvent removal gave a solid which was recrystallized from EtOAc to give compound **6** as a white solid (520 mg, 47%): mp 177–178 °C; [α]_D = –92.1 (CHCl_3 , $c = 1.3$); IR 2923, 1738, 1371, 1200, 1072, 960 cm^{-1} ; $^{13}\text{C-NMR}$ δ 221.44, 66.32, 54.33, 51.45, 47.76, 39.03, 35.98, 35.80, 35.74, 35.01, 32.02, 31.52, 30.79, 28.95, 28.21, 21.70, 20.0, 13.78; $^1\text{H-NMR}$ δ 4.05 (1H, m); 0.86 (3H, s); HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{27}\text{D}_3\text{O}_2$, MH^+ 294.2507; found 294.2510; >95% d_3 .

(5 α , 8 α , 9 β , 10 α , 13 α , 14 β , 17 α)-17-Hydroxyandrostane-3-one-19,19,19- d_3 (7)—KOH (0.48 g) and $i\text{PrOH}$ (30 mL) were added to a hydrogenation bottle, the solution was stirred for 30 min to allow some of the KOH to dissolve. Pd/C (0.11 g, 5%) and *ent*-steroid **3** (2 g, 6.8 mmol) dissolved in $i\text{PrOH}$ (30 mL) were then added and the total volume was increased to ~100 mL with $i\text{PrOH}$. The solution was hydrogenated using a Parr hydrogenator for 18 h at 45 psi and the catalyst removed by filtration through a pad of Celite which was washed with MeOH. After removal of the solvent, a yellow oil remained. To this oil, brine (150 mL) and Et₂O (250 mL) were added, and the aqueous phase was neutralized with 6 N HCl. After thorough mixing, the aqueous layer was removed and the organic layer was washed with brine (3 $\times$ 200 mL) and dried. Solvent removal gave a white solid. Column chromatography (silica gel, 20% EtOAc/hexanes to 40% EtOAc/hexanes) separated ketoalcohol **4** from an inseparable mixture of ketoalcohol **7** and diol **8**. Acetylation of the mixture of products **7** and **8** in the standard manner⁹ (pyridine 5.48 mL, acetic anhydride 5.35 mL, DMAP, catalytic amount) gave acetylation products **9** and **10** which were easily separated by column chromatography (silica gel, 180 gms 5–15% 3 $\times$ 500 cm^3 EtOAc in hexanes). Saponification of **9** using K_2CO_3 (200 mg and MeOH 20 mL, reflux for an hour and purification by column chromatography on silica gel eluted with 30% EtOAc in hexanes) gave pure product **7** as a white solid (730 mg, 37%): mp 140–141 °C; [α]_D = –28.90 (EtOH, $c = 0.6$); IR 2865, 1712, 1073, 855 cm^{-1} ; $^{13}\text{C-NMR}$ δ 213.24, 81.78, 50.96, 44.21, 43.09, 42.27, 40.87, 37.14, 36.91, 36.79, 35.57, 34.72, 30.52, 26.43, 25.33, 23.32, 20.76, 11.09; $^1\text{H-NMR}$ δ 3.6 (1H, t, $J = 8.5$ Hz), 2.67 (1H, t, $J = 14.3$ Hz), 0.76 (3H, s); HRMS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{27}\text{D}_3\text{O}_2$, MH^+ 294.2507; found 294.2513.

(5 α , 8 α , 9 β , 10 α , 13 α , 14 β)-Androstane-3,17-dione-19,19,19- d_3 (11)—Compound **7** (730 mg, 2.48 mmol) was dissolved in acetone (20 mL) and while stirring Jones reagent (8 M) was titrated dropwise to this solution until a yellow color persisted. The solution was stirred

at room temperature for 30 min after which *i*PrOH was titrated dropwise to quench any remaining Jones reagent. The reaction mixture was poured into brine (150 mL) and the aqueous solution was extracted with EtOAc (3 × 200 mL). The organic extracts were combined and dried. After solvent removal, a blue solid remained. This solid was chromatographed (silica gel, 50% EtOAc in hexanes) to yield compound **11** (560 mg, 77%) as a white solid: mp 125–126 °C; $[\alpha]_D = -104.66$ (EtOH, *c* = 0.4); IR 2931, 1738, 1712, 1373, 1202, 1093, 915 cm^{-1} ; ^{13}C -NMR δ 220.66, 212.60, 51.30, 47.72, 44.03, 42.13, 40.90, 37.01, 36.76, 35.75, 35.04, 34.74, 31.57, 26.25, 24.61, 21.67, 20.39, 13.70; ^1H -NMR δ 2.68 (1H, t, *J* = 14.2 Hz), 0.89 (3H, s); HRMS (ESI) *m/z* calcd for $\text{C}_{19}\text{H}_{25}\text{D}_3\text{O}_2$, MH^+ 292.2350; found 292.2350.

ent-Etiocholanolone-19,19,19- d_3 (12**)**—To a dry flask compound **11** (560 mg, 1.92 mmol) dissolved in dry THF (30 mL) was added. While under N_2 , the solution was cooled to -42°C in a bath of acetonitrile and dry ice. Lithium tri-*tert*-butoxyaluminumhydride (1.9 mL, 2 mmol, 1 M in THF) was added dropwise and the solution was stirred for 2 h at -42°C under N_2 . TLC after 2 h confirmed that reaction was not complete, hence it was warmed to -20°C for another 1 h. The reaction was quenched with 3 N HCl (20 mL). EtOAc (250 mL) was added and the organic solution was washed with aqueous NaHCO_3 (150 mL) and brine (150 mL). The organic layer was dried and the solvent was removed to give a white solid. Column chromatography (silica gel, 30% EtOAc/hexanes) yielded product **12** (480 mg, 80%) as a white solid: mp 149–150 °C; $[\alpha]_D = -95.3$ (EtOH, *c* = 0.7); IR 2929, 1738, 1370, 1089, 947 cm^{-1} ; ^{13}C -NMR δ 221.35, 71.59, 51.45, 47.82, 41.92, 40.69, 36.27, 35.89, 35.39, 35.19, 34.48, 31.69, 30.44, 26.86, 25.33, 21.78, 20.04, 13.75; ^1H -NMR δ 3.67–3.60 (1H, m), 2.44 (dd, *J* = 18.9, 8.7 Hz), 0.85 (3H, s); HRMS (ESI) *m/z* calcd for $\text{C}_{19}\text{H}_{27}\text{D}_3\text{O}_2$ MH^+ 294.2507; found 294.2508; >95% d_3 .

Conclusion

An efficient synthesis of *ent*-testosterone, *ent*-androsterone and *ent*-etiocholanolone containing 19,19,19- d_3 deuterium labeling was developed.

Acknowledgements

This work was supported by NIH grant GM47969.

References

1. Kaminski RM, Marini H, Kim WJ, Rogawski MA. *Epilepsia* 2005;46(6):819–825. [PubMed: 15946323]
2. Akk G, Covey DF, Evers AS, Steinbach JH, Zorumski CF, Mennerick S. *Pharm & Therapeutics* 2007;116:35–57.
3. Katona BW, Krishnan K, Cai ZY, Manion BD, Benz A, Taylor A, Evers AS, Zorumski CF, Mennerick S, Covey DF. *Eur J Med Chem* 2008;43:107–113. [PubMed: 17434649]
4. Hu Y, Wittmer LL, Kalkbrenner M, Evers AS, Zorumski CF, Covey DF. *J Chem Soc, Perkin Trans* 1997;1:3665–3671.
5. Baba S, Sinhora Y, Kasuya Y. *J of Lab Compds and Radiopharm* 1978;14(5):783–91.
6. Djerassi C, Kielczewski MA. *Steroids* 1963;2:125–134.
7. Rychnovsky SD, Mickus DE. *J Org Chem* 1992;57:2732–2736.
8. Covey DF. *Polish J Chem* 2006;80:511–522.
9. Westover EJ, Covey DF. *Steroids* 2003;68:159–166. [PubMed: 12606007]

Figure 1.
Target compounds: 19-Trideuterated Androgens.

Scheme 1.

Synthesis of *ent*-testosterone-19,19,19-*d*₃ (**3**); Reagents: (a) i. Li/liq. NH₃, THF; ii. CD₃I; (b) 3 N HCl, MeOH. For complete description of the preparation of compound **1** see references. 7,8

Scheme 2.

Synthesis of *ent*-androsterone-19,19,19-*d*₃ (**6**). Reagents: (a) Li/Li NH₃, THF, toluene, NH₄Cl (b) Jones reagent, acetone, 0° C (c) i. K-selectride®, THF; ii. 10% NaOH, 30% aqueous H₂O₂.

Scheme 3.

Synthesis of *ent*-etiocholanolone-19,19,19-*d*₃ (**12**). (a) Pd/C, KOH, *i*PrOH, H₂; (b) Acetic anhydride, Pyridine, DMAP; (c) K₂CO₃, MeOH; (d) LiAl[(OC(CH₃)₃)₃H, THF.